Riskpilot← Back to searchSign inGet full accessLG Läkarkonsult AB
ABActiveOrg 5592567647Svampskogsvägen 35General medical practice activities · NACE 8621Est. 20201 employees
Revenue 2025
SEK 2,5M
-1% vs 2024
EBITDA margin
7.6%
-49% vs 2024
Equity ratio
14.8%
Financial strength
Net profit 2025
SEK 104K
-50% vs 2024
| Revenue | SEK 2,5M | -1% |
| EBITDA | SEK 188K | -49% |
| Net profit | SEK 104K | -50% |
| Total assets | SEK 919K | -7% |
| Equity | SEK 136K | -43% |
| Employees | 1 | — |
Legal name
LG Läkarkonsult AB
Org number
5592567647
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
20 maj 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva sjukvård, medicinsk konsultverksamhet samt förvaltning av värdepapper och fastigheter. Bolaget skall vidare ha verksamhet inom fjällaktiviteter och äventyrsarrangemang med evenemang inom fjällvärlden och därmed förenlig verksamhet.
Address
Svampskogsvägen 35
Email
dubrovskay@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 801 | 2 169 | 2 265 | 2 515 | 2 478 |
| Staff expenses | — | −1 434 | −1 808 | −1 925 | −1 982 |
| EBITDA | 282 | 582 | 252 | 370 | 188 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 282 | 582 | 252 | 370 | 188 |
| Net financials | — | −1 | −58 | −5 | −0 |
| Profit before tax | 210 | 434 | 127 | 268 | 136 |
| Tax | −45 | −91 | −42 | −60 | −32 |
| Net profit | 165 | 343 | 85 | 208 | 104 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 894 | 1 171 | 804 | 992 | 919 |
| Equity | 331 | 384 | 129 | 237 | 136 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 354 | 431 | 252 | 234 | 212 |
| Total debt | 354 | 431 | 252 | 234 | 212 |
EBITDA margin
7.6%
This company
15.8%
Market median
-52% vs market
20212025
Equity ratio
14.8%
This company
38.2%
Market median
-61% vs market
20212025
Return on equity
76.6%
This company
18.4%
Market median
+316% vs market
20212025
Net profit margin
4.2%
This company
8.1%
Market median
-48% vs market
20212025
Asset turnover
2.70×
This company
1.12×
Market median
+141% vs market
20212025
Debt / equity
5.77×
This company
0.62×
Market median
-831% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LG Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vira Slivina | Board of Directors | 0 companies |
| Hans Ingvar Backle | Deputy Board Member | 0 companies |